top of page

The Full Story

Tirzepatide
Monjaro

Dual GIP and GLP-1 receptor agonist for diabetes and weight management

mounjaro-1296x728-header-1296x729.avif
Mounjaro-tirzepatid-tirzepatide-diabetes.jpeg

Exceptional Weight Loss

Clinical programs consistently show 15–22% average weight reduction, leading the category.

Heart Health Benefits

Improves cardiometabolic markers while maintaining effective glycemic control.

FDA Approved*

Breakthrough therapy approved for diabetes and widely used in weight-management protocols.

Contraindications and Precautions

Contraindications:

  • Personal or family history of medullary thyroid carcinoma

  • Multiple Endocrine Neoplasia syndrome type 2

  • Known hypersensitivity to tirzepatide

Use with Caution:

  • History of pancreatitis

  • Severe renal impairment

  • Diabetic retinopathy

  • Pregnancy and breastfeeding

Why Choose Tirzepatide?

Tirzepatide is a dual GIP and GLP-1 receptor agonist that addresses appetite regulation, glucose control, and metabolic efficiency—providing durable outcomes for patients who haven’t responded to traditional options.

Patient Story:
“I’m down 43 pounds in 12 weeks with Tirzepatide. My energy is steady, cravings are way down, and my A1c is finally in range.” – Olivia P.

Mechanism of Action

  • GLP-1 Receptor Activation: Stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon, and slows gastric emptying.

  • GIP Receptor Activation: Enhances insulin sensitivity and may directly affect fat metabolism.

  • Appetite Regulation: Acts on brain receptors to reduce appetite and food intake.

  • Gastric Motility: Slows gastric emptying, increasing satiety.

Transformative Results

Diabetes Management:

  • Significant reduction in HbA1c levels

  • Improved glycemic control

  • Low risk of hypoglycemia

  • Cardiovascular benefits

Weight Management Success:

  • Average weight loss of 15–22% in clinical trials

  • Sustained weight reduction

  • Improved body composition

  • Reduction in waist circumference

Clinical Trial Highlights:

In the SURMOUNT trials, patients achieved an average of 20.9% weight loss at the highest dose — results that set a new standard in weight-management therapy.

Dosing and Administration

Route: Subcutaneous injection once weekly

Starting Dose: 2.5 mg once weekly for 4 weeks

Maintenance Doses:

  • 5 mg once weekly (minimum effective dose)

  • 7.5 mg once weekly

  • 10 mg once weekly

  • 12.5 mg once weekly

  • 15 mg once weekly (maximum dose)

Injection Sites: Thigh, abdomen, or upper arm. Rotate injection sites weekly.

Side Effects — Common (≥5%)

  • Nausea (12–18%)

  • Diarrhea (12–16%)

  • Vomiting (6–12%)

  • Constipation (6–7%)

  • Abdominal pain (6–9%)

  • Injection site reactions

Side Effects — Serious (Rare)

  • Pancreatitis

  • Gallbladder disease

  • Kidney problems

  • Severe hypoglycemia (with insulin/sulfonylureas)

  • Thyroid C-cell tumors (theoretical risk)

 

  •  

*Regulatory notes vary by indication and region. This content is informational only and not a substitute for medical advice. Patients should consult their licensed provider.

bottom of page